Insulet Stock News

Parametric Portfolio Associates LLC increased its stake in shares of Insulet Co. (NASDAQ:PODD) by 14.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 71,128 shares of the medical instruments suppliers stock after purchasing an additional 9,080 shares during the period. Parametric Portfolio Associates LLC owned 0.10% []

ACTON, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the virtual 45 th Nasdaq Investor Conference on Friday,

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management

Analysts forecast that Insulet Co. (NASDAQ:PODD) will post sales of $298.38 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Insulets earnings. The lowest sales estimate is $283.40 million and the highest is $308.50 million. Insulet posted sales of $246.10 million during the same quarter last year, which []

Berman Capital Advisors LLC increased its position in Insulet Co. (NASDAQ:PODD) by 151.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 965 shares of the medical instruments suppliers stock after purchasing an additional 581 shares during the quarter. Berman []

J.P. Morgan Stick to Their Buy Rating for Insulet

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Insulet Corporation (PODD) CEO Shacey Petrovic on Q3 2021 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of -9.09% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Insulet share price appears to have raced too high, providing outstanding historical returns but little margin for future growth. Insulet requires some heroic assumptions on revenue growth and unit co

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System.  Omnipod 5 is a tubeless, wearable system that continuo

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented po

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced